152 related articles for article (PubMed ID: 32517736)
1. 2,6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo.
Zu X; Ma X; Xie X; Lu B; Laster K; Liu K; Dong Z; Kim DJ
J Exp Clin Cancer Res; 2020 Jun; 39(1):107. PubMed ID: 32517736
[TBL] [Abstract][Full Text] [Related]
2. 2,6-DMBQ suppresses cell proliferation and migration via inhibiting mTOR/AKT and p38 MAPK signaling pathways in NSCLC cells.
Xie X; Zu X; Laster K; Dong Z; Kim DJ
J Pharmacol Sci; 2021 Mar; 145(3):279-288. PubMed ID: 33602509
[TBL] [Abstract][Full Text] [Related]
3. 2,6-Dimethoxy-1,4-benzoquinone increases skeletal muscle mass and performance by regulating AKT/mTOR signaling and mitochondrial function.
Yoo A; Jang YJ; Ahn J; Jung CH; Ha TY
Phytomedicine; 2021 Oct; 91():153658. PubMed ID: 34332284
[TBL] [Abstract][Full Text] [Related]
4. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
5. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
[TBL] [Abstract][Full Text] [Related]
6. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
7. Methylxanthine derivatives promote autophagy in gastric cancer cells targeting PTEN.
Liu H; Song J; Zhou Y; Cao L; Gong Y; Wei Y; Yang H; Tang L
Anticancer Drugs; 2019 Apr; 30(4):347-355. PubMed ID: 30875347
[TBL] [Abstract][Full Text] [Related]
8. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative and antimetabolic effects behind the anticancer property of fermented wheat germ extract.
Otto C; Hahlbrock T; Eich K; Karaaslan F; Jürgens C; Germer CT; Wiegering A; Kämmerer U
BMC Complement Altern Med; 2016 Jun; 16():160. PubMed ID: 27245162
[TBL] [Abstract][Full Text] [Related]
11. ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer.
Kawakami R; Mashima T; Kawata N; Kumagai K; Migita T; Sano T; Mizunuma N; Yamaguchi K; Seimiya H
Cancer Sci; 2020 Mar; 111(3):962-973. PubMed ID: 31960523
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
13. CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo.
Yan Y; Du C; Li G; Chen L; Yan Y; Chen G; Hu W; Chang L
Urol Oncol; 2018 Jun; 36(6):312.e1-312.e8. PubMed ID: 29566977
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of gastric cancer cell growth by a PI3K-mTOR dual inhibitor GSK1059615.
Bei S; Li F; Li H; Li J; Zhang X; Sun Q; Feng L
Biochem Biophys Res Commun; 2019 Mar; 511(1):13-20. PubMed ID: 30765226
[TBL] [Abstract][Full Text] [Related]
15. Huachansu Capsule inhibits the proliferation of human gastric cancer cells via Akt/mTOR pathway.
Ni T; Wang H; Li D; Tao L; Lv M; Jin F; Wang W; Feng J; Qian Y; Sunagawa M; Liu Y
Biomed Pharmacother; 2019 Oct; 118():109241. PubMed ID: 31351435
[TBL] [Abstract][Full Text] [Related]
16. Rab1A knockdown represses proliferation and promotes apoptosis in gastric cancer cells by inhibition of mTOR/p70S6K pathway.
Li Z; Li Y; Jia Y; Ding B; Yu J
Arch Biochem Biophys; 2020 May; 685():108352. PubMed ID: 32240637
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer.
Matsuzaki T; Yashiro M; Kaizaki R; Yasuda K; Doi Y; Sawada T; Ohira M; Hirakawa K
Cancer Sci; 2009 Dec; 100(12):2402-10. PubMed ID: 19764996
[TBL] [Abstract][Full Text] [Related]
18. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
20. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
